NSTGQ vs. PMCB, APTO, SNTI, TVGN, IKT, COEP, ONVO, BCDA, CHRO, and TTNP
Should you be buying NanoString Technologies stock or one of its competitors? The main competitors of NanoString Technologies include PharmaCyte Biotech (PMCB), Aptose Biosciences (APTO), Senti Biosciences (SNTI), Tevogen Bio (TVGN), Inhibikase Therapeutics (IKT), Coeptis Therapeutics (COEP), Organovo (ONVO), BioCardia (BCDA), Chromocell Therapeutics (CHRO), and Titan Pharmaceuticals (TTNP). These companies are all part of the "biological products, except diagnostic" industry.
PharmaCyte Biotech (NASDAQ:PMCB) and NanoString Technologies (NASDAQ:NSTGQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
In the previous week, PharmaCyte Biotech had 1 more articles in the media than NanoString Technologies. MarketBeat recorded 2 mentions for PharmaCyte Biotech and 1 mentions for NanoString Technologies. NanoString Technologies' average media sentiment score of 0.94 beat PharmaCyte Biotech's score of 0.00 indicating that PharmaCyte Biotech is being referred to more favorably in the media.
34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 76.8% of NanoString Technologies shares are held by institutional investors. 7.3% of PharmaCyte Biotech shares are held by insiders. Comparatively, 3.1% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
PharmaCyte Biotech and NanoString Technologies both received 0 outperform votes by MarketBeat users.
PharmaCyte Biotech has higher earnings, but lower revenue than NanoString Technologies. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
PharmaCyte Biotech has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
PharmaCyte Biotech has a net margin of 0.00% compared to PharmaCyte Biotech's net margin of -102.44%. PharmaCyte Biotech's return on equity of 0.00% beat NanoString Technologies' return on equity.
Summary
PharmaCyte Biotech beats NanoString Technologies on 7 of the 12 factors compared between the two stocks.
Get NanoString Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSTGQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NSTGQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NSTGQ vs. The Competition
NanoString Technologies Competitors List
Related Companies and Tools
